Friday, February 16, 2018 9:14:19 AM
“Fluvoxamine (SSRI) 17.0
Sertraline (SSRI) 31.6
Fluoxetine (SSRI) 191.2
Escitalopram (SSRI) 288.3
Citalopram (SSRI) 403.8
Paroxetine (SSRI) 2041
Duoxetine (SNRI) 3533
Venlafaxine (SNRI) >10,000 Milnacipran (SNRI) >10,000 Mirtazapine (NaSSA) >10,000
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication
https://ac.els-cdn.com/S1347861314000176/1-s2.0-S1347861314000176-main.pdf?_tid=188f1d70-1319-11e8-a85c-00000aab0f01&acdnat=1518786094_9ee528a53583943bed94a71e95778fce
· Donepezil (Aricept®) is a potent acetylcholinesterase inhibitor that is used in treating Alzheimer's disease. The compound is also a potent sigma-1 receptor ligand with an affinity of 14.6 nM
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785038/
The receptor binding profile of Anavex 2-73 is:
Ki of 860 nM for sigma 1 receptor
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118560971
Probably a decent idea to read the above link imho.
“Usually, the *lower* the Ki number, the more affinity; which is measured by the displacement of another (radiolabled for example) exogenous ligand.”
“For binding affinity people generally are referring to either the dissociation constant (the Kd value) or the association constant, Ka, which has no units. For your question why does it seem backwards, well Ka = 1/Kd. If units are given it is usually referring to Kd, the equilibrium dissociation constant (equilibrium referring to the binding and unbinding reactions).
Ki, or the inhibition constant, has to do with competitive binding assays and relates the ligand with the amount of competitor that displaces half of it (the IC50). “
http://www.bluelight.org/vb/threads/774430-Receptor-Binding-affinity-meaning-and-units
“The affinity is measured by the concentration required to get 50% binding. If it is 5 nM for one compared to 50 uM for another, then it takes 10,000 times more ligand to get the same binding for the 50 uM compound as the 5 nM compound. However, the binding tells you nothing about the efficacy. The strongly bound compound could be a partial agonist and the weakly binding compound could be a full agonist, or vice versa. So, the 5 nM compound is stronger on a weight basis, but may not have stronger effects at equivalent doses.”
Sertraline (SSRI) 31.6
Fluoxetine (SSRI) 191.2
Escitalopram (SSRI) 288.3
Citalopram (SSRI) 403.8
Paroxetine (SSRI) 2041
Duoxetine (SNRI) 3533
Venlafaxine (SNRI) >10,000 Milnacipran (SNRI) >10,000 Mirtazapine (NaSSA) >10,000
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication
https://ac.els-cdn.com/S1347861314000176/1-s2.0-S1347861314000176-main.pdf?_tid=188f1d70-1319-11e8-a85c-00000aab0f01&acdnat=1518786094_9ee528a53583943bed94a71e95778fce
· Donepezil (Aricept®) is a potent acetylcholinesterase inhibitor that is used in treating Alzheimer's disease. The compound is also a potent sigma-1 receptor ligand with an affinity of 14.6 nM
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785038/
The receptor binding profile of Anavex 2-73 is:
Ki of 860 nM for sigma 1 receptor
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118560971
Probably a decent idea to read the above link imho.
“Usually, the *lower* the Ki number, the more affinity; which is measured by the displacement of another (radiolabled for example) exogenous ligand.”
“For binding affinity people generally are referring to either the dissociation constant (the Kd value) or the association constant, Ka, which has no units. For your question why does it seem backwards, well Ka = 1/Kd. If units are given it is usually referring to Kd, the equilibrium dissociation constant (equilibrium referring to the binding and unbinding reactions).
Ki, or the inhibition constant, has to do with competitive binding assays and relates the ligand with the amount of competitor that displaces half of it (the IC50). “
http://www.bluelight.org/vb/threads/774430-Receptor-Binding-affinity-meaning-and-units
“The affinity is measured by the concentration required to get 50% binding. If it is 5 nM for one compared to 50 uM for another, then it takes 10,000 times more ligand to get the same binding for the 50 uM compound as the 5 nM compound. However, the binding tells you nothing about the efficacy. The strongly bound compound could be a partial agonist and the weakly binding compound could be a full agonist, or vice versa. So, the 5 nM compound is stronger on a weight basis, but may not have stronger effects at equivalent doses.”
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
